Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia
This is a Phase I trial investigating the safety of using thioridazine in addition to cytarabine in elderly patients with relapsed or refractory Acute Myeloid Leukemia.
Acute Myeloid Leukemia
DRUG: Thioridazine
Safety, Both acute and late toxicities will be determined according to NCI-CTCAE version 4.03, Up to 36 days
Assessment of Functional Leukemia Stem Cells, Bone marrow and peripheral blood samples obtained from patients treated with thioridazine and cytarabine will be analyzed in four separate assays., Up to 36 days|Pharmacokinetic Analysis of Thioridazine Serum Trough Levels, Pharmacokinetic modeling will be performed to estimate values for individual C min levels., Up to 36 days|Assessment of Objective Tumor Response, Tumor responses are categorized as either a complete remission, a complete remission with incomplete count recovery, a partial remission, a treatment failure, or as not evaluable, Up to 36 days|Pharmacogenetic Analysis of Thioridazine Serum Trough Levels, Cytochrome P450 2D6 genotype will be determined to examine genetic contribution to thioridazine Cmin levels., Up to 36 days
This is a Phase I trial investigating the safety of using thioridazine in addition to cytarabine in elderly patients with relapsed or refractory Acute Myeloid Leukemia.